Savara Inc. (NASDAQ:SVRA)
Industry: Healthcare

Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial and lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant staphylococcus aureus lung infection in individuals living with cystic fibrosis. The company is headquartered in Austin, Texas.

Current Quote*
Last: $7.030
Change: 0.030
Book: $2.044
Volume: 38,167

As Of: 02/15 13:37 ET
*Quotes delayed by 20min.

Graphs for SVRA

3 Month Graph

6 Month Graph

1 Year Graph